Fate Therapeutics' P/S ratio aligns with peers due to predic...
Fate Therapeutics' P/S ratio aligns with peers due to predicted revenue drop in following years. Given forecasted revenue slide and below par industry growth, future share price gains may be minimal. It's vital to consider the company's future prospects and not just its P/S ratio when deciding to sell stock.
Fate Therapeutics, Inc.'s (NASDAQ:FATE) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment